


Inhibition of MicroRNA miR-222 with LNA Inhibitor Can Reduce Cell Proliferation in B Chronic Lymphoblastic Leukemia

Korosh Ashrafi Dehkordi¹  · Morteza Hashemzadeh Chaleshtori² ·
Mohamadreza Sharifi³ · Ali Jalili⁴ · Fardin Fathi⁴ · Daem Roshani⁵ ·
Bahram Nikkhoo⁶ · Mohammad Saeed Hakhamaneshi⁴ ·
Mohammad Reza Mahmoodian Sani^{7,8} · Mahboue Ganji-Arjenaki⁹

Received: 3 March 2016 / Accepted: 4 June 2016
© Indian Society of Haematology & Transfusion Medicine 2016

Abstract MicroRNAs (miRNAs) are small regulatory molecules that negatively regulate gene expression by base-pairing with their target mRNAs. miRNAs have contributed significantly to cancer biology and recent studies have demonstrated the oncogenic or tumor-suppressing role in cancer cells. In many tumors up-regulation of miRNAs has been reported especially miR-222 has been shown to be up-regulated in B chronic lymphocytic leukemia (B-CLL). In this study we assessed the effect of inhibition of miR-222 in cell viability of B-CLL. We performed inhibition of miR-222 in B-CLL cell line (183-E95) using locked nucleic

acid (LNA) antagomir. At different time points after LNA-anti-miR-222 transfection, miR-222 quantitation and cell viability were assessed by qRT-real time polymerase chain reaction and MTT assays. The data were analyzed by independent *t* test and one way ANOVA. Down-regulation of miR-222 in B-CLL cell line (183-E95) with LNA antagomir decreased cell viability in B-CLL. Cell viability gradually decreased over time as the viability of LNA-anti-miR transfected cells was <47 % of untreated cells at 72 h post-transfection. The difference in cell viability between LNA-anti-miR and control groups was statistically significant ($p < 0.042$). Based on our findings, the inhibition of miR-222 may represent a potential novel therapeutic approach for treatment of B-CLL.

✉ Korosh Ashrafi Dehkordi
kdashrafi@gmail.com

¹ Student Research Committee, Kurdistan University of Medical Sciences, Pasdaran Street, Sanandaj 66177-13446, Iran

² Cellular and Molecular Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran

³ Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

⁴ Cellular and Molecular Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran

⁵ Social Determinants of Health Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran

⁶ Department of Pathology and Clinical Laboratory Sciences, Kurdistan University of Medical Sciences, Sanandaj, Iran

⁷ Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran

⁸ Department of Genetics and Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran

⁹ Department of Genetics, Faculty of Basic Sciences, Shahrekord University, Shahrekord, Iran

Keywords MicroRNA · miR-222 · Chronic lymphocytic leukemia · Locked nucleic acid

Introduction

MiRNAs are a family of 19–25-nucleotide small RNAs that negatively regulate gene expression at the post-transcriptional level by binding to the 3′-untranslated region of target mRNA [1, 2]. miRNAs play essential roles in many normal biological processes involving cell proliferation, differentiation, growth and development, metabolism, aging and apoptosis [3–7]. Recently, the role of microRNAs (miRNAs) in cancer has received much attention, much evidence points to miRNAs functioning as tumor promoters (oncomirs) such as: miR-155 and miR-17–92 [8], or tumor suppressors (anti-oncomirs) such as: miR-15a, miR-16, and miRNAs of the miR-34 and let-7 families [8, 9]. miRNA alterations are effective on all six hallmarks of malignant cells; in CLL, the main effects

are apoptosis, evasion, self-sufficiency in growth, and as recently found, stimulation of dissemination and angiogenesis [10].

Chronic lymphocytic leukemia (CLL) is a disease of older patients, and with most patients ≥ 65 years of age and having at least one major property [11, 12], CLL is of B cell origin, it occurs in two forms, indolent and aggressive [11]. The most frequency chromosomal abnormalities detected in CLL include deletion at 13q (55 %), 11q (18 %), trisomy 12 (12–16 %) and 17p (8 %) but molecular details still under investigation [13, 14]. MicroRNAs in CLL can function as oncogenes, tumor suppressors, or be used as markers for disease onset/progression for example, in indolent CLL, 13q14 deletions targeting miR-15/16 initiate the disease, while in aggressive CLL miR-181 targets the critical TCL1 oncogene [11, 15]. The relative expression levels of certain microRNAs correlate with prognostic indicators in CLL for example, leukemia-cell expression of zeta-associated protein of 70 kDa (ZAP-70), use of unmutated immunoglobulin heavy-chain variable region genes (IGHV) [16–19]. miR-221/222 are highly homologous miRNAs encoded in tandem on the X chromosome, Amplification or overexpression of miR-221/222 is reported in hematopoietic malignancies indicating that miR-221/222 could be potential therapeutic targets [20]. The direct association between miR-222 and B-cell malignancies is indicated, upregulation of human miR-222 was reported in aggressive forms of CLL, glioblastoma, and thyroid papillary carcinoma [20–22]. The miR-221/222 cluster is capable of modulating the expression of p27 gene, it is a regulatory loop that contributes to keeping CLL cells in resting condition [20].

In this study, we knockdown mir-222 by locked nucleic acid (LNA), then evaluation expression of mir-222 and cell viability in 183-E95 cell line at 24,48,72 h after inhibition.

Materials and Methods

Cell Culture

The 183-E95 cell line was purchased from the National Cell Bank of Iran (NCBI; Pasteur Institute, Iran). The cell culture was maintained in Roswell Park Memorial Institute (RPMI) 1640 (Gibco, Paisley, UK) supplemented with fetal calf serum (FCS; Gibco, Paisley, UK) 15 % v/v, 100 U/mL of penicillin and 100 μ g/mL of streptomycin (Gibco, Paisley, UK) in a humid and air-saturated atmosphere consisting of 5 % CO₂ inside 25-cm² culture flasks (Nunc, Roskilde, Denmark) at 37 °C. The cells were passaged twice a week to keep an exponential growth phase.

Cell Transfection

The nucleotide sequences of miR-222 were obtained from www.mirbase.org as GAG ACC CAG TAG CCA GAT GTA GCT. The miRCURY LNA microRNA InhibitorTM for hsa-miR-222 and miRNA inhibitor negative control (scrambled) oligonucleotides were purchased from Exiqon, Denmark. Both oligonucleotides were labeled at the 5' end with fluorescent dyes, 6-FAM, for subsequent detection of transfected cells.

183-E95 cell transfection was performed by the Lipofectamin RNAiMax transfection Reagent (Invitrogen Germany) according to the manufacturer instructions. Briefly, 5×10^5 cells in the exponential growth phase were cultured in six-well culture plates (Nunc, Roskilde, Denmark) containing 1.8 mL RPMI 1640 per well without antibiotics and FCS. The 30 pmol mercury locked nucleic acids (LNA) microRNA inhibitorTM was mixed with 5 μ L Lipofectamin RNAiMax Transfection ReagentTM in 200 μ L Opti-MEMI MediumTM (Gibco, Paisley, UK) and incubated for 15 min at room temperature. Then, the complex was added to the cells and swirled carefully for even distribution over the entire plate surface. After 8-h incubation, the FCS and antibiotics were added, and the cells were incubated for 24, 48, and 72 h. Untreated and scrambled-LNA transfected cells were cultured parallel to the LNA anti-miR transfected cells. Efficiency of the transfection was investigated by flow cytometry and fluorescent microscopy. LNA was conjugated with 6 FAMTM Fluorescein (6-carboxyfluorescein) to identify and quantify LNA transfected cells by fluorescent microscopy and FACSCalibur flow cytometer (Partec, Germany).

Reverse Transcriptase micRNA Real Time Polymerase Chain Reaction (PCR)

First the expression level of mir-222 in B-CLL cell line (183-E95) was determined by qRT-real time PCR. Reverse transcriptase (RT) miRNA real time PCR was done to determine the efficiency of miR-222 inhibition using LNA anti-miR. Briefly, the total cellular RNA was extracted 24, 48, and 72 h post-transfection with the miRCURY RNA Isolation KitTM (Genall) and cDNA was synthesized with the Universal cDNA Synthesis KitTM (Parsgengan). Real time PCR was performed by SYBR Green Master Mix KitTM (Takara) and specific miR-222 primers (all consumables in this section were from Metabion, Germany). Synthetic RNA Snord 47 templates and their primers (Metabion, Germany) were used for real time PCR internal control. The ABI Step One Plus (ABI, USA) instrument was used for real time PCR experiments and the $2^{-\Delta\Delta C_t}$ method for data calculation.

Cells Viability Assay

The viability of cells was determined by the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay, based on reduction of MTT by the mitochondrial dehydrogenase of intact cells to purple formazan products. The conversion is directly related to the number of living cells. The MTT assay was performed at the intervals of 24, 48, and 72 h post-transfection. Two hundred μ L of MTT (Sigma-Aldrich, USA) at the concentration of 50 mg/mL was added to 5×10^5 183-E95 cells suspended in 2 mL of RPMI 1640 medium and incubated for 4 h at 37 °C in the darkness. Two hundred μ L of dimethyl sulfoxide (Sigma-Aldrich, USA) was added to each well and was shaken until dissolution of crystals. Blank samples were prepared per exactly the same procedure except for cell incorporation. Absorbance was measured by a spectrophotometer at 570 nm. Reading was converted to the percentage of the controls.

Statistical Analysis

Statistical analyses were performed using SPSS version 16.0. independent t test and one-way ANOVA was used for the analysis of the differences between groups. A p value of <0.05 was considered statistically significant. All experiments were replicated three times.

Results

miRCURY LNA microRNA InhibitorTM powerfully Inhibits expression of miR-222

The up-regulation of miR-222 was showed in B-CLL cell line (183-E95) by qRT-real time PCR. For inhibition of miR-222, the miRCURY LNA microRNA InhibitorTM was transfected to 183-E95 cells with the Lipofectamin RNAiMax Transfection Reagent. On the basis of the initial optimization experiments, transfection was performed with 30 pM of LNA-anti-miR and 5 μ L of the transfection reagent. As the transfected oligonucleotides were fluorochrome-conjugated, transfection efficiencies were assessed by fluorescence microscopy and flow cytometry. Carefully optimized protocol produced transfection efficiency of 80 % (Fig. 1).

Expression of miR-222 was assessed by reverse transcriptase microRNA real time PCR in 183-E95 cells transfected with the miRCURY LNA microRNA InhibitorTM (LNA-anti-miR group); the microRNA inhibitor scrambled oligonucleotides (scrambled LNA group) and untreated 183-E95 cells (untreated groups) at 24, 48, and 72 h post-transfection. Although miR-222 expression was a

little lower in the scrambled LNA-transfected cells compared to the untreated cells, the differences were not statistically significant. However, in all three intervals, the expression of miR-222 was considerably lower in the LNA-anti-miR group compared to the control groups ($p < 0.0037$). The expression of miR-222 was at the lowest level at 48 h after transfection (Fig. 2).

Expression of miR-222 in B-CLL cell line (183-E95) in three groups: scrambled, LNA-anti-miR222 and untreated determined by quantitative RT-PCR. Numeral upper columns is p value result of compared between groups. Values shown represent the mean \pm SD.

Inhibition of miR-222 Decreased Viability 183-E95 Cells

To assess the effect of miR-222 inhibition on cell viability, the MTT assay was performed at 24, 48, and 72 h post-transfection. Cell viability was lower in LNA-anti-miR group compared to the untreated cells at 48 and 72 h post-transfection ($p < 0.05$). The effect of LNA-anti-miR transfection on the cell viability increased over time as the viability of the LNA-anti-miR transfected cell was $<47\%$ of the untreated cells at 72 h post-transfection. The difference in the cell viability between the LNA-anti-miR and both control groups (untreated and scrambled treated) was statistically significant ($p < 0.042$) at all three intervals (Fig. 3).

The viability of the untreated cells in each time point was considered as 100 % and the viability of other groups is presented as the percentage of the untreated cells in the same time point. Data were mean \pm SD of three independent experiments.

Discussion

B-cell chronic lymphocytic leukemia (B-CLL), also known as chronic lymphoid leukemia (CLL) is a type of cancer of the white blood cells in adult [5, 23]. CLL has a variable course. Some patients require little or no treatment, but in some other patients, the disease is progressive and results in the death despite various treatments. Effective choices of treatment are available for CLL patients, including chemotherapy and monoclonal antibodies [24, 25]. These types of treatments can induce remissions in up to 90 % of patients. Some patients, however, do not respond to upfront chemoimmunotherapy combinations, or they develop resistance to the treatment quickly. Despite recent progresses in treatment of this disorder, because of the effects of chemotherapy and radiotherapy, including adverse effects on normal cells, seeking for new therapies seems necessary. In the recent years, it has been demonstrated that

Fig. 1 Transfection miR-222 show with fluorescent microscope and flow cytometry 183-E95 cells have been transfected with 6-FAMTM fluorescein-conjugated LNA oligonucleotides and then to assess transfection efficiency, they analyzed by flow cytometry and have been observed with a fluorescent microscope. Phase contrast (a) and fluorescent (b) images of the same field of 183-E95 cells show that a majority of the cells were transfected. Representative FSC-SCS and FL1-Count flow cytometry graphs are shown in c. Scale bars 50 μ m





Fig. 2 Evaluation of miR-222 by qRT-PCR performed 24, 48, and 72 h after trasfection

small regulatory non-coding RNAs (ncRNAs) named microRNAs (miRNAs) are involved in human tumorigenesis. Since miRNAs can function as either oncogenes or tumor suppressor genes in tumorigenesis, the potential of using these small RNAs as therapeutic targets opens up new opportunities for cancer treatments by either inhibiting or augmenting their activity [26].

Among miRNAs significantly deregulated in human cancer, miR-221/222 are of major interest potential targets for therapeutic application. miR-221/222 act as oncogenic




Fig. 3 Evaluation of cell viability by the MTT assay performed 24, 48, and 72 h after transfection

miRNAs that as facilitate cell proliferation via down-regulation of p27^{KIP1} and/or p57^{KIP2} [27], as potential targets for therapeutic applications, which negatively regulate cell cycle progression from G1- to S-phase [28]. p27 binds to cyclin-dependent kinase 2 and cyclin E complexes to prevent cell-cycle progression from G1 to S phase. Several reports suggested a key role of miR-221/222 in tumorigenesis. In addition, other authors recently showed that miR-

221/222 antisense oligonucleotides reduce tumor growth by increasing intra-tumor p27^{KIP1} protein expression [29].

A evidence suggests that silencing microRNAs with oncogenic potential may represent a successful therapeutic strategy for human cancer. A new therapeutic strategy to inhibit miRNAs that are involved in the pathogenesis of the disease, which is the aim of the present study, we can use engineered nucleic acid (LNA) that create a stable connection with the target miRNA and are resistant to nucleases. They particularly disrupt the performance of specific molecule (miR) which plays a role in prevalence of cancer [30, 31]. In this study we used LAN-anti-mir to inhibit mir-222 in B-CLL in cell line 183-E95, Prevention of cellular proliferation subsequent to the LNA transfection is indicative of successful inhibition of miR-222 in the cell line under study. Real time PCR confirmed our data and miRNAs reduced expression almost by transfection of LNA. MTT test showed that inhibition of mir-222 caused reduction of viability cell after 24, 48 and 72 h. Cell viability had the minimal reduction in LNA-scrambled and in comparison to untreated cells with no significant difference.

There are many articles related to oncomir that show treatment with this method is used for many types of cancers. Inhibition effect of miR-221 by anti-miRNA oligonucleotide in CLL p53-mutant MEG-01 cells, significant increase in caspase activity in fludarabine-treated in cell line [32]. The up expression of miR-221/222 in the CLL cell line MEC1 promote down-regulation of p27 protein therefore miR-221/222 and p27 may exhibit a regulatory loop that helps maintaining CLL cells in a resting condition [20]. The up expression of miR-92a in APL cell line (HL-60) by LNA antagomir extensively decreased cell viability [33]. The difference of cell viability between LNA-anti-miR and control groups was statistically significant ($p < 0.024$). In a study by Di Martino et al. [34] on the in vitro effect of inhibiting miR-221/222 on cancer cell multiple myeloma, LNA technology was used to inhibit miR-221/222. Their studies showed that by inhibiting miR-221/222 in cell multiple myeloma, p27^{KIP1}, PUMA and PTEN genes that all have the role of tumor suppressor in cell cycle are increased but decreased in reverse cell proliferation. More recently, it has been reported that the treatment with LNA-modified miR-221 inhibitors reduces the growth of liver cancer cells over-expressing miR-221/222 in vitro by targeting a DNA damage-inducible transcript 4 (DDIT4), a modulator of the mTOR pathway [35].

Chemotherapy is a routine treatment in CLL. But, different findings have been obtained in cases resistant to treatment. On the other hand, there are some instances that oncomiR inhibition acts to sensitize the cells to chemotherapy agents, making this combination therapy

influenced more than any one of the strategies used alone. Our data suggest that inhibition of miR-222 with LNA-anti-miR may provide an alternative approach for the treatment of B-CLL. It can be used alone or in combination with current therapies to reduce the existing limitations in the treatment of this malignancy.

Acknowledgments Hereby, we gratefully thank Kurdistan University of Medical Sciences.

Compliance with Ethical Standards

Conflict of interest The authors have no conflicts of interest, including financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.

Ethical Approval This article does not contain any studies with human participants or animals performed by any of the authors.

References

1. Winter J, Diederichs S (2011) MicroRNA biogenesis and cancer. *Methods Mol Biol* 676:3–22
2. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R (2006) Control of translation and mRNA degradation by miRNAs and siRNAs. *Genes Dev* 20(5):515–524
3. Gibb EA, Brown CJ, Lam WL (2011) The functional role of long non-coding RNA in human carcinomas. *Mol Cancer* 10:38
4. O'Connell RM, Rao DS, Baltimore D (2012) microRNA regulation of inflammatory responses. *Ann Rev Immunol* 30(1):295–312
5. Alvarez-Garcia I, Miska EA (2005) MicroRNA functions in animal development and human disease. *Development* 132(21):4653–4662
6. Griffiths-Jones S (2006) miRBase: the microRNA sequence database. *Methods Mol Biol* 342:129–138
7. Rottiers V, Naar AM (2012) MicroRNAs in metabolism and metabolic disorders. *Nat Rev Mol Cell Biol* 13(4):239–250
8. Kwak PB, Iwasaki S, Tomari Y (2010) The microRNA pathway and cancer. *Cancer Sci* 101(11):2309–2315
9. Yamakuchi M, Lowenstein CJ (2009) MiR-34, SIRT1, and p53: the feedback loop. *Cell Cycle* 8(5):712–715
10. Cho WC (2010) MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. *Int J Biochem Cell Biol* 42(8):1273–1281
11. Balatti V, Pekarky Y, Rizzotto L, Croce CM (2013) miR deregulation in CLL. Springer, *Adv Chronic Lymph Leuk*, pp 309–325
12. Byrd JC, Harrington B, Brien S, Jones JA, Schuh A, Devereux S et al. (2015) Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. *N Engl J Med* 374(4):323–332
13. Gunnarsson R, Mansouri L, Isaksson A, Göransson H, Cahill N, Jansson M et al (2011) Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia. *Haematologica* 96(8):1161–1169
14. Matutes E, Oscier D, Garcia-Marco J, Ellis J, Copplestone A, Gillingham R et al (1996) Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients. *Br J Haematol* 92(2):382–388
15. Pekarsky Y, Croce CM (2015) Role of miR-15/16 in CLL. *Cell Death Differ* 22(1):6–11

16. Mraz M, Kipps TJ (2013) MicroRNAs and B cell receptor signaling in chronic lymphocytic leukemia. *Leuk Lymphoma* 54(8):1836–1839
17. Said JW, Hoyer KK, French SW, Rosenfelt L, Garcia-Lloret M, Koh PJ et al (2001) TCL1 oncogene expression in B cell subsets from lymphoid hyperplasia and distinct classes of B cell lymphoma. *Lab Invest* 81(4):555–564
18. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD et al (2004) MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. *Proc Natl Acad Sci USA* 101(32):11755–11760
19. Calin GA, Croce CM (2009) Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes. *Blood* 114(23):4761–4770
20. Frenquelli M, Muzio M, Scielzo C, Fazi C, Scarfò L, Rossi C et al (2010) MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27. *Blood* 115(19):3949–3959
21. Visone R, Russo L, Pallante P, De Martino I, Ferraro A, Leone V et al (2007) MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27^{KIP1} protein levels and cell cycle. *Endocr Relat Cancer* 14(3):791–798
22. Hao J, Zhang C, Zhang A, Wang K, Jia Z, Wang G et al (2012) miR-221/222 is the regulator of Cx43 expression in human glioblastoma cells. *Oncol Rep* 27(5):1504–1510
23. Giza DE, Calin GA (2015) microRNA and chronic lymphocytic leukemia. In: Santulli G (ed) *microRNA: cancer. From molecular biology to clinical practice*, vol 889. Springer, Berlin, pp 23–40
24. Cho WC (2010) MicroRNAs in cancer—from research to therapy. *Biochim Biophys Acta Rev Cancer* 1805(2):209–217
25. Pastorkova Z, Skarda J, Andel J (2016) The role of microRNA in metastatic processes of non-small cell lung carcinoma: a review. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub* 160(1):1–15
26. Chan E, Prado DE, Weidhaas JB (2011) Cancer microRNAs: from subtype profiling to predictors of response to therapy. *Trends Mol Med* 17(5):235–243
27. Medina R, Zaidi SK, Liu C-G, Stein JL, Croce CM, Stein GS (2008) MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. *Cancer Res* 68(8):2773–2780
28. le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A et al (2007) Regulation of the p27Kip1 tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. *EMBO J* 26(15):3699–3708
29. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafrè SA et al (2007) miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. *J Biol Chem* 282(32):23716–23724
30. Cho WC (2010) MicroRNAs in cancer—from research to therapy. *Biochim Biophys Acta* 1805(2):209–217
31. Cho WC (2010) MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. *Int J Biochem Cell Biol* 42(8):1273–1281
32. Ruiz-Lafuente N, Alcaraz-García M-J, Sebastián-Ruiz S, García-Serna A-M, Gómez-Espuch J, Moraleda J-M et al (2015) IL-4 up-regulates MiR-21 and the MiRNAs hosted in the CLCN5 gene in chronic lymphocytic leukemia. *PLoS One* 10(4):e0124936
33. Sharifi M, Salehi R, Gheisari Y, Kazemi M (2014) Inhibition of microRNA miR-92a induces apoptosis and inhibits cell proliferation in human acute promyelocytic leukemia through modulation of p63 expression. *Mol Biol Rep* 41(5):2799–2808
34. Di Martino MT, Gullà A, Cantafio MEG, Lionetti M, Leone E, Amodio N et al (2013) In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. *Oncotarget* 4(2):242
35. Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B et al (2010) miR-221 overexpression contributes to liver tumorigenesis. *Proc Natl Acad Sci* 107(1):264–269